Várady E, Molnár Z, Schneider T, Fleischmann T
Országos Onkológiai Intézet, Budapest, Haematologiai Osztaly.
Orv Hetil. 1995 Oct 22;136(43):2323-8.
Between 1978 and 1993, 1013 patients 529 with Hodgkin's disease and 484 with non-Hodgkin's lymphomas--were treated in our department. Out of 1013 patients secondary neoplasms developed in 23 cases: 3 acute nonlymphocytic leukemia, 19 solid tumors and 1 secondary non-Hodgkin's lymphoma. The median time from diagnosis of malignant lymphoma was 7 years and their median age was 49 years. 11 patients with secondary tumor were treated with chemotherapy and 12 received combined (radio- and chemo-) therapy. Since alkylating agents increase the risk of leukemia and radiation contributes mainly to other cancer, future treatment protocols should attempt to reduce the most serious consequences of therapy without compromising the survival. Careful lifelong observation is indicated for patients with malignant lymphomas, with special attention given to new clinical signs or symptoms.
1978年至1993年间，我科共治疗了1013例患者，其中529例为霍奇金病患者，484例为非霍奇金淋巴瘤患者。在1013例患者中，有23例发生了继发性肿瘤：3例急性非淋巴细胞白血病、19例实体瘤和1例继发性非霍奇金淋巴瘤。从恶性淋巴瘤诊断到发生继发性肿瘤的中位时间为7年，患者的中位年龄为49岁。11例继发性肿瘤患者接受了化疗，12例接受了联合（放疗和化疗）治疗。由于烷化剂会增加白血病风险，而放疗主要导致其他癌症，未来的治疗方案应在不影响生存率的前提下，尽量减少治疗的最严重后果。对于恶性淋巴瘤患者，需要进行仔细的终身观察，特别关注新出现的临床体征或症状。
